Antibody Testing

Patients may become sensitized to HLA antigens through pregnancies, blood transfusions or transplantations and develop HLA antibodies.

The presence of these pre-formed anti-HLA antibodies may lead to acute or chronic graft rejection or failed platelet transfusion. When present in blood donors, HLA antibodies may passively transfer to recipients and lead to development of transfusion-related acute lung injury (TRALI). HLA antibodies can be identified and characterized using various techniques.

Antibody Identification

HLA Class I and Class II antibody screening and identification tests are performed to help identify the most compatible donors for a patient in need of platelet transfusion or transplantation who may have developed allogeneic HLA antibodies. In addition, these tests help clinicians to monitor the patient’s post-transplant/transfusion immune status for therapeutic purposes.

Antibody Screening

HLA Class I and Class II antibody screening is also used in testing plasma samples from the implicated blood donors and patients for leukocyte antibodies in evaluation of a suspected TRALI case. In addition, blood donors known to be leukocyte-alloimmunized or at increased risk of leukocyte alloimmunization are tested for HLA antibodies.

Find the resources you need.